Studies have been found successful tocilizumab treatment of RP-ILD in anti-MDA5 antibody-positive DM patients [33]; we have also successfully treated an NXP-2 antibody-positive DM patient with tocilizumab [34]. Here, MORC3 is linked to dermatomyositis.